

BIOMARIN PHARMACEUTICAL INC

Form 4

June 03, 2008

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
KAKKIS EMIL D

2. Issuer Name **and** Ticker or Trading
Symbol

**BIOMARIN PHARMACEUTICAL
INC [BMRN]**

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction

(Month/Day/Year)

06/02/2008

____ Director ____ 10% Owner
____X____ Officer (give title ____ Other (specify
below) below)

Chief Medical Officer

**C/O BIOMARIN
PHARMACEUTICAL INC., 105
DIGITAL DRIVE**

(Street)

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)

____X____ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

NOVATO, CA 94949

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/02/2008 ⁽¹⁾	06/02/2008	M		16,000	A	\$ 4	178,804	D	
Common Stock	06/02/2008 ⁽¹⁾	06/02/2008	S		458	D	\$ 37.57	178,346	D	
Common Stock	06/02/2008 ⁽¹⁾	06/02/2008	S		731	D	\$ 37.58	177,615	D	
Common Stock	06/02/2008 ⁽¹⁾	06/02/2008	S		600	D	\$ 37.59	177,015	D	
	06/02/2008 ⁽¹⁾	06/02/2008	S		3,911	D	\$ 37.6	173,104	D	

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common
Stock

Common Stock	06/02/2008 ⁽¹⁾	06/02/2008	S	1,300	D	\$ 37.61	171,804	D
Common Stock	06/02/2008 ⁽¹⁾	06/02/2008	S	1,200	D	\$ 37.62	170,604	D
Common Stock	06/02/2008 ⁽¹⁾	06/02/2008	S	1,400	D	\$ 37.63	169,204	D
Common Stock	06/02/2008 ⁽¹⁾	06/02/2008	S	1,200	D	\$ 37.64	168,004	D
Common Stock	06/02/2008 ⁽¹⁾	06/02/2008	S	3,252	D	\$ 37.65	164,752	D
Common Stock	06/02/2008 ⁽¹⁾	06/02/2008	S	1,648	D	\$ 37.66	163,104	D
Common Stock	06/02/2008 ⁽¹⁾	06/02/2008	S	1,000	D	\$ 37.67	162,104	D
Common Stock	06/02/2008 ⁽¹⁾	06/02/2008	S	1,300	D	\$ 37.71	160,804	D

Common
Stock

4,654

I

Shares
held by
spouse

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 4	06/02/2008 ⁽¹⁾	06/02/2008	M		16,000		12/24/1998 ⁽²⁾	06/21/2008	Common Stock	16,000

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KAKKIS EMIL D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949			Chief Medical Officer	

Signatures

G. Eric Daivs,
Attorney-in-Fact

06/03/2008

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to a Rule10b5-1 Trading Plan executed March 5, 2008.

(2) Original option grant vested 6/48ths on 12/24/1998 and 1/48th on the 24th of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.